Call 888-776-0942 from 8 a.m. to 10 p.m. Eastern Time

Shanghai, November 15, 2021/PRNewswire/ - Qiming Ventures’ portfolio company Aohua Endoscopy (Shanghai Stock Exchange code: 688212), a leading manufacturer of medical endoscopes, is now available on Kechuang plate. The issue price is RMB 22.5 per share. The opening price of the stock was 33 yuan per share, with a market value of 4.4 billion yuan. Qiming Ventures led the company's C round of financing in 2016, followed by D round of financing.

The listing of the Aohua logo is the third IPO of Qiming's portfolio in the past month after Abisco (HKEx code: 2256) and Weike Medical (HKEx code: 2235). As of 2021, Qiming has completed 12 public listings in our portfolio.

Aohua Endoscope specializes in the R&D, manufacturing and sales of electronic endoscope equipment and surgical consumables. After two decades of innovation, Aohua's full range of endoscope products have been widely used in clinical fields such as gastroenterology, respiratory medicine, otolaryngology, gynecology, and emergency departments.

Aohua Endoscope entered the flexible electronic endoscope market in China earlier. The company's product layout is systematic, and it has been committed to innovation and development of talents for a long time. It has made breakthroughs in endoscope optical imaging, image processing, mirror body design, and electrical control. Aohua's soft endoscopes entered the developed markets very early, including Germany, the United Kingdom and South Korea.

Aohua Endoscopy CEO Gu Xiaozhou said: "Our mission is to make endoscopic diagnosis and treatment more popular and convenient. For more than 20 years, the company has been clinically demand-oriented and focused on building a manufacturing system. In the future, we will continue to strengthen our research and development, Advantages in product, distribution and talent development to produce better domestic endoscope products."

Hu Wei, managing partner of Qiming Ventures, said: "Qiming Ventures has witnessed the growth of Aohua Endoscopy. The company has a solid R&D team and organizational structure, and adheres to the close integration of technology improvement and product upgrades with clinical practice. The IPO is Aohua Endoscopy. As a new starting point for endoscopes, we look forward to becoming the world's leading provider of total endoscope solutions, accelerating the localization of high-end medical equipment, and benefiting the majority of patients."

Established in 2006, Qiming Venture Capital is a leading venture capital company in China with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area.

Qiming Ventures currently manages 10 USD funds and 6 RMB funds, raising a total of USD 6.2 billion. Since our establishment, we have invested in outstanding companies in the early and growth stages of TMT and the healthcare industry.

Since its debut, we have supported more than 430 fast-growing and innovative companies. More than 170 companies have been listed on the New York Stock Exchange, Nasdaq, Hong Kong Stock Exchange, Getty Securities Market, Shanghai Stock Exchange and Shenzhen Stock Exchange, or have exited through mergers and acquisitions. More than 40 portfolio companies have gained unicorn status.

Many of our portfolio companies are the most influential companies in their respective industries today, including Xiaomi (HKEx code: 1810), Meituan (HKEx code: 3690), Bilibili (Nasdaq) Code: BILI, Hong Kong Stock Exchange Code: 9626), Stone Technology (Shanghai Stock Exchange Code: 688169), Gan & Lee Pharmaceuticals (SHSE: 603087), Tigermed (SZSE: 300347, SEHK: 3347), Zai Lab (NASDAQ: ZLAB, SEHK) :9688), Venus MedTech (SEHK:2500), CanSino Biologics (SEHK:6185, SHSE:68818), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), New Horizon Health (SEHK:6606) , Sanyou Medical (SHSE: 688085), Amoy (SZSE: 300685), Berry Genomics (SZSE:0007Tech10), Sinocell SHSE: 688520), WeDoctor Group and Ubico, etc.

More news releases on similar topics

Cision Distribution 888-776-0942 8 a.m. to 9 p.m. Eastern Time